2019

Ho KM, Rao S, Honeybul S, Zellweger R, Wibrow B, Lipman J, Holley A, Kop A, Geelhoed E, Corcoran T, Misur P, Edibam C, Baker RI, Chamberlain J, et al. A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. N Engl J Med. 2019 Jul 25; 381(4):328-337.

Oh J, Oh D, Lee SJ, Kim JH, Kim NK, Chong SY, Huh JY, Baker RI. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Research 2019; 54(3): 218-228.

Favaloro EJ, Gilmore G, Arunachalam S, Mohammed S, Baker RI. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thromb Res. 2019 Aug; 180:10-19.

2018

Wines BD, Tan CW, Duncan E, McRae S, Baker RI, Andrews RK, et al. Dimeric FcγR ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia. J Thromb Haemost. 2018 Dec; 16 (12):2520-2525.

2017

Hughes QW, Le BT, Gilmore G, Baker RI, Veedu RN. Construction of a Bivalent Thrombin Binding Aptamer and its Antidote with Improved Properties. Molecules. 2017 Oct 19; 22 (10). pii: E1770.

Tay JW, James I, Hughes QW, Tiao JY, Baker RI. Identification of reference miRNAs in plasma useful for the study of oestrogen-responsive miRNAs associated with acquired Protein S deficiency in pregnancy. BMC Res Notes. 2017 Jul 25; 10(1):312.

Tay JW, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating microRNA as thrombosis sentinels: Caveats and considerations. Seminars in Thrombosis and Hemostasis. 2017.

Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J, Shapiro AD, Baker RI, Bennett CM, et al.  Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 Feb 28; 117(3):508-518.

Quon DV, Klamroth R, Kulkarni R, Shapiro AD, Baker RI, Castaman G, et al. Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies. Haemophilia. 2017 Jan; 23(1): e39-e42.

2016

Tay, JW, Tiao, J, Hughes, Q, Gilmore, G and Baker, R (2016) Therapeutic Potential of miR-494 in Thrombosis and Other Diseases: A Review. Australian Journal of Chemistry 2016 Jan; 69 (10)

Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellmann A, Santagostino E, Baker RI, Fischer K, et al; AFFINITY Investigators. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 Aug 4; 128 (5):630-7.

2015

Qiao J, Al-Tamimi M, Baker RI, Andrews RK, et al. The platelet Fc receptor, FcγRIIa. Immunol Rev. 2015 Nov; 268(1):241-52.

Metharom P, Berndt MC, Baker RI, Andrews RK. Current state and novel approaches of antiplatelet therapy. Arterioscler Thromb Vasc Biol. 2015 Jun; 35(6):1327-38.

2014

Baker RI, McGregor SR. Does preoperative laboratory monitoring of antithrombotic therapy avoid adverse outcomes in patients undergoing surgery or regional anaesthesia? Anaesth Intensive Care. 2014 Sep; 42(5):555-7.

2013

Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12;369 (24):2313-23.

Tay JW, Romeo G, Hughes QW, Baker RI. Micro-ribonucleic Acid 494 regulation of protein S expression. J Thromb Haemost. 2013 Aug; 11(8):1547-55.

Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013 May; 161(3):411-23.